Biolinerx Stock Today
| BLRX Stock | USD 0.32 0.23 41.82% |
Performance0 of 100
| Odds Of DistressOver 83
|
BioLineRx is trading at 0.32 as of the 22nd of November 2024; that is 41.82 percent decrease since the beginning of the trading day. The stock's open price was 0.55. BioLineRx has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for BioLineRx are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of May 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of July 2011 | Category Healthcare | Classification Health Care |
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modiin, Israel. Biolinerx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 79.94 M outstanding shares of which 1.06 M shares are currently shorted by private and institutional investors with about 2.39 trading days to cover. More on BioLineRx
Moving together with BioLineRx Stock
| 0.72 | VRAX | Virax Biolabs Group | PairCorr |
| 0.66 | VRPX | Virpax Pharmaceuticals | PairCorr |
| 0.75 | DYN | Dyne Therapeutics | PairCorr |
| 0.76 | XFOR | X4 Pharmaceuticals | PairCorr |
Moving against BioLineRx Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
BioLineRx Stock Highlights
| Vice President-Development | Ella Sorani | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBioLineRx can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BioLineRx's financial leverage. It provides some insight into what part of BioLineRx's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BioLineRx (BLRX) is traded on NASDAQ Exchange in USA. It is located in Modi?in Technology Park, Hevel Modi'in, Israel, 7177871 and employs 79 people. BioLineRx is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 44.52 M. BioLineRx conducts business under Biotechnology sector and is part of Health Care industry. The entity has 79.94 M outstanding shares of which 1.06 M shares are currently shorted by private and institutional investors with about 2.39 trading days to cover.
BioLineRx currently holds about 43.15 M in cash with (22.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check BioLineRx Probability Of Bankruptcy
Ownership AllocationBioLineRx holds a total of 79.94 Million outstanding shares. BioLineRx shows 8.53 percent of its outstanding shares held by insiders and 3.07 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check BioLineRx Ownership Details
BioLineRx Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Two Sigma Securities, Llc | 2024-06-30 | 46.2 K | |
| Orin Green Financial, Llc | 2024-09-30 | 43 K | |
| Geode Capital Management, Llc | 2024-06-30 | 40 K | |
| Rathbone Brothers Plc | 2024-06-30 | 39.8 K | |
| Geneos Wealth Management Inc | 2024-06-30 | 38.5 K | |
| Gradient Investments | 2024-09-30 | 30 K | |
| Rhumbline Advisers | 2024-06-30 | 25.7 K | |
| Weaver Consulting Group | 2024-06-30 | 16.9 K | |
| Cutter & Co Brokerage, Inc. | 2024-09-30 | 16.7 K | |
| Alyeska Investment Group, L.p. | 2024-06-30 | 2 M | |
| Cvi Holdings Llc | 2024-06-30 | 815.7 K |
BioLineRx Historical Income Statement
BioLineRx Stock Against Markets
BioLineRx Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Raziel Fried | Treasurer Director | Profile | |
| Adam Esq | General Compliance | Profile | |
| Jael MSc | QA RA | Profile | |
| CPA MBA | Chief Officer | Profile |
Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.